830 related articles for article (PubMed ID: 8101864)
1. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.
Martin PJ
J Exp Med; 1993 Aug; 178(2):703-12. PubMed ID: 8101864
[TBL] [Abstract][Full Text] [Related]
2. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism.
Martin PJ
Blood; 1996 Aug; 88(3):962-9. PubMed ID: 8704255
[TBL] [Abstract][Full Text] [Related]
3. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice.
Vallera DA; Taylor PA; Sprent J; Blazar BR
Transplantation; 1994 Jan; 57(2):249-56. PubMed ID: 7906058
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
5. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice.
Drobyski WR; Majewski D
Blood; 1997 Feb; 89(3):1100-9. PubMed ID: 9028343
[TBL] [Abstract][Full Text] [Related]
6. A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers.
Koch U; Korngold R
Blood; 1997 Apr; 89(8):2880-90. PubMed ID: 9108408
[TBL] [Abstract][Full Text] [Related]
7. Multilineage engraftment with minimal graft-versus-host disease following in utero transplantation of S-59 psoralen/ultraviolet a light-treated, sensitized T cells and adult T cell-depleted bone marrow in fetal mice.
Bhattacharyya S; Chawla A; Smith K; Zhou Y; Talib S; Wardwell B; Cowan MJ
J Immunol; 2002 Dec; 169(11):6133-40. PubMed ID: 12444116
[TBL] [Abstract][Full Text] [Related]
8. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway.
Ito H; Kurtz J; Shaffer J; Sykes M
J Immunol; 2001 Mar; 166(5):2970-81. PubMed ID: 11207246
[TBL] [Abstract][Full Text] [Related]
9. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
[TBL] [Abstract][Full Text] [Related]
10. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD.
Petrus MJ; Williams JF; Eckhaus MA; Gress RE; Fowler DH
Biol Blood Marrow Transplant; 2000; 6(2A):182-9. PubMed ID: 10816026
[TBL] [Abstract][Full Text] [Related]
11. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mixed lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity.
Pierce GE
Transplantation; 1990 Jan; 49(1):138-44. PubMed ID: 2137269
[TBL] [Abstract][Full Text] [Related]
13. Role of CD28 in acute graft-versus-host disease.
Yu XZ; Martin PJ; Anasetti C
Blood; 1998 Oct; 92(8):2963-70. PubMed ID: 9763584
[TBL] [Abstract][Full Text] [Related]
14. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.
Palathumpat V; Dejbakhsh-Jones S; Strober S
Transplantation; 1995 Aug; 60(4):355-61. PubMed ID: 7652765
[TBL] [Abstract][Full Text] [Related]
15. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
[TBL] [Abstract][Full Text] [Related]
16. Prevention and restoration of second-set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms.
Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S
Transplantation; 1999 Feb; 67(3):444-50. PubMed ID: 10030293
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow.
Blazar BR; Taylor PA; Sehgal SN; Vallera DA
Blood; 1994 Jan; 83(2):600-9. PubMed ID: 8286755
[TBL] [Abstract][Full Text] [Related]
18. Alloresistance to K locus class I-mismatched bone marrow engraftment is mediated entirely by CD4+ and CD8+ T cells.
Hayashi H; LeGuern C; Sachs DH; Sykes M
Bone Marrow Transplant; 1996 Aug; 18(2):285-92. PubMed ID: 8864436
[TBL] [Abstract][Full Text] [Related]
19. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
Waller EK; Boyer M
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
[TBL] [Abstract][Full Text] [Related]
20. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
Johnson BD; Truitt RL
Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
